Curi Bio Acquires South Korea-based Quvit Bio

BioIVT Acquires ZenBio

August 21, 2024

Healthcare Services

BioIVT has acquired ZenBio, a Durham-based provider of advanced cell products and biospecimen services, to expand its skin-based expertise, primary cell and exosome isolation capabilities, and blood product offerings for pharmaceutical and cosmetics research. The deal strengthens BioIVT's service portfolio and complements recent integrations to accelerate support for drug discovery and cosmeceutical development; financial terms were not disclosed.

GC Corp Signs Definitive Agreement to Acquire BioCentriq, Inc.

April 19, 2022

Healthcare Services

GC corp., the holding (system) company for the GC group in South Korea, signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc. BioCentriq is a US-based CDMO focused on scalable cell and gene technology development and cGMP-grade clinical manufacturing.

Curia (formerly AMRI) to Acquire Integrity Bio, Inc.

July 13, 2021

Healthcare Services

Curia (formerly AMRI) has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California. The acquisition is intended to expand Curia’s biologics drug product formulation development and enhance its fill-finish network, including adding West Coast coverage.

Curi (Curi Capital) Acquires RMB Capital to Form Curi RMB Capital

January 2, 2024

Wealth Management

Curi completed its previously announced acquisition of RMB Capital and merged Curi Capital with RMB to form Curi RMB Capital, a registered investment advisory firm with more than $11.3 billion in assets under advisement. The combined firm is headquartered in Chicago, retains leadership from both organizations, and has approximately 180 employees while positioning itself for expanded geographic reach and long-term growth.

Asahi Kasei Acquires Aicuris Anti-infective Cures AG

February 26, 2026

Biotechnology

Asahi Kasei entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million (about $919 million). The deal is expected to close in the first quarter of fiscal 2026, subject to customary conditions, and is intended to strengthen Asahi Kasei’s specialty pharmaceutical platform in severe infectious diseases.

Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities

February 14, 2022

Biotechnology

Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.